戻る Agenda
Patient Engagement in Pharmacovigilance
Session Chair(s)
Deborah Collyar
President
Patient Advocates In Research (PAIR), United States
This session will present current research and emerging best practices in the field of patient risk communication, including methods for collecting patient input in the design of these communication materials.
Learning Objective : Identify key elements that are needed to make patient educational materials understandable and actionable for patients in their decision-making process regarding treatment; Examine the value of patient-generated real-world safety data, public hearings, and patient input into the development of risk communication tools.
Speaker(s)
Patient Engagement and Pharmacovigilance: Risk Interventions and Strategic Communications (RISC)
Emily Freeman, PHD, MSC
Gilead, Inc., United States
Senior Director, Patient Engagementg, Global Medical Strategyand Operations
How Will EU Public Hearings Help with Patient and Public Engagement and How Should the Industry Prepare?
Shelley Gandhi, MSC
Eliquent Life Sciences, United Kingdom
Partner & PV trainer
Can Patient-Generated Real-World Data Illuminate Real World Evidence of Safety Concerns Sooner Than Traditional Sources?
David Blaser, PHARMD
PatientsLikeMe, United States
Director, Health Informatics
How Well Are We Doing Conveying Drug Safety Information to Patients? An Analysis of the Quality of REMS Educational Materials
Meredith Yearsley Smith, PHD, MPA, FISPE
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, United States
Fellow and faculty member